2. Search Result
Search Result
Results for "

anticonvulsant properties

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Peptides

3

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1932
    Cortistatin-14

    		Somatostatin Receptor Neurological Disease Inflammation/Immunology Endocrinology
    Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .
    Cortistatin-14
  • HY-B0696A
    Tiagabine hydrochloride

    NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride

    		 GABA Receptor Neurological Disease
    Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride
  • HY-105296
    Blarcamesine
    3 Publications Verification

    		 Sigma Receptor mAChR Cancer
    Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
    Blarcamesine
  • HY-B0696
    Tiagabine

    NO050328; NO328; TGB

    		 GABA Receptor Neurological Disease
    Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine
  • HY-B1122
    L-Cycloserine
    2 Publications Verification

    (S)-Cycloserine; (S)-4-Amino-3-isoxazolidone

    		 GABA Receptor HIV Neurological Disease Cancer
    L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains .
    L-Cycloserine
  • HY-B1657A
    Fosphenytoin disodium

    		Sodium Channel Neurological Disease
    Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin disodium
  • HY-16579
    Etifoxine hydrochloride
    3 Publications Verification

    HOE 36-801 hydrochloride

    		 GABA Receptor Neurological Disease
    Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine hydrochloride
  • HY-16579A
    Etifoxine
    3 Publications Verification

    HOE 36-801

    		 GABA Receptor Neurological Disease
    Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine
  • HY-W008344
    2-Chloroadenosine

    		Nucleoside Antimetabolite/Analog Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    2-Chloroadenosine is an adenosine analog, a transporter permeabilizer of nucleoside transporters, and a competitive uridine influx inhibitor (apparent Ki=33 μM). 2-Chloroadenosine binds to nitrobenzylthioinosine with high affinity (apparent Ki=0.18 mM). 2-Chloroadenosine promotes Apoptosis and increases cerebral blood flow. 2-Chloroadenosine has anticonvulsant properties. 2-Chloroadenosine is used to study infection, inflammatory diseases, cancer, blood-related diseases, lung injury, epilepsy, and kidney disease .
    2-Chloroadenosine
  • HY-14953
    Imepitoin

    AWD 131-138

    		 GABA Receptor Neurological Disease
    Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
    Imepitoin
  • HY-W749797
    Nitrazolam

    		GABA Receptor Neurological Disease
    Nitrazolam is a benzodiazepine compound, that may exhibit CNS depressant properties as traditional benzodiazepines, including sedation, hypnosis, anxiolysis, and anticonvulsant effects, by acting on GABA receptors .
    Nitrazolam
  • HY-14953R
    Imepitoin (Standard)

    AWD 131-138 (Standard)

    		 GABA Receptor Reference Standards Neurological Disease
    Imepitoin (Standard) is the analytical standard of Imepitoin. This product is intended for research and analytical applications. Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
    Imepitoin (Standard)
  • HY-177986
    NCR 631

    		Drug Derivative Neurological Disease
    NCR 631 is a 3-HAO inhibitor and 3-hydroxyanthranilic acid (HY-W001171) analogue. NCR-631 has anticonvulsant properties. NCR-631shows a concentration-dependent protective effect against the anoxia .
    NCR 631
  • HY-123229
    Ropizine

    SC 13504

    		 Others Neurological Disease
    Ropizine (SC 13504) is a benzhydryl piperazine with anticonvulsant properties .
    Ropizine
  • HY-105115
    Abecarnil

    ZK 112119

    		 GABA Receptor Neurological Disease
    Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABAA receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC50 of 0.82 nM. Abecarnil can be used for epilepsy research .
    Abecarnil
  • HY-B0696B
    Tiagabine hydrochloride hydrate

    NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate

    		 GABA Receptor Neurological Disease
    Tiagabine (NO050328; NO328; TGB) hydrochloride hydrate is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride hydrate exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride hydrate is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride hydrate
  • HY-107323
    Bentazepam

    QM 6008; Thiadipone; Tiadipone

    		 GABA Receptor Neurological Disease
    Bentazepam (Thiadipone) is a compound with short-action anxiolytic effect. Bentazepam shows anticonvulsant and sedative properties. Bentazepam can be used for the research of depressive disorder and anxiety .
    Bentazepam
  • HY-107323A
    Bentazepam hydrochloride

    QM 6008 hydrochloride; Thiadipone hydrochloride; Tiadipone hydrochloride

    		 GABA Receptor Neurological Disease
    Bentazepam (QM 6008, Thiadipone) hydrocholide is a compound with short-action anxiolytic effect. Bentazepam hydrocholide shows anticonvulsant and sedative properties. Bentazepam hydrocholide can be used for the research of depressive disorder and anxiety .
    Bentazepam hydrochloride
  • HY-119146
    Zolazepam

    CI-716 free base

    		 Drug Derivative Neurological Disease
    Zolazepam (CI-716 free base) is a benzodiazepine derivative with anxiolytic and anticonvulsant properties. Zolazepam combined with Tiletamine causes a decrease in ventilation, resulting in the development of respiratory acidosis. Zolazepam can be used as sedative and muscle relaxants .
    Zolazepam
  • HY-B1657AS
    Fosphenytoin-d10 disodium

    		Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Fosphenytoin-d10 (disodium) is deuterium labeled Fosphenytoin (disodium). Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin-d10 disodium
  • HY-B1657AR
    Fosphenytoin disodium (Standard)

    		Reference Standards Sodium Channel Neurological Disease
    Fosphenytoin (disodium) (Standard) is the analytical standard of Fosphenytoin (disodium). This product is intended for research and analytical applications. Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin disodium (Standard)
  • HY-16579AS2
    Etifoxine-d5

    		GABA Receptor Neurological Disease
    Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine-d5
  • HY-16579AR
    Etifoxine (Standard)

    HOE 36-801 (Standard)

    		 Reference Standards GABA Receptor Neurological Disease
    Etifoxine (Standard) is the analytical standard of Etifoxine. This product is intended for research and analytical applications. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine (Standard)
  • HY-160978
    Timelotem

    KC-7507 free base

    		 GABA Receptor Neurological Disease
    Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders .
    Timelotem
  • HY-B1122R
    L-Cycloserine (Standard)

    (S)-Cycloserine (Standard); (S)-4-Amino-3-isoxazolidone (Standard)

    		 Reference Standards GABA Receptor HIV Neurological Disease Cancer
    L-Cycloserine (Standard) is the analytical standard of L-Cycloserine. This product is intended for research and analytical applications. L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains[1][2][3][4].
    L-Cycloserine (Standard)
  • HY-118758
    γ-Kainylglutamic acid

    γ-Kainic acid-glutamic acid

    		 Sodium Channel Neurological Disease
    γ-Kainylglutamic acid (γ-Kainic acid-glutamic acid), a dipeptide derived from kainic and L-Glutamic acids, is a selective antagonist of amino acid induced neuroexcitation with anticonvulsant properties. γ-Kainylglutamic acid inhibits the stimulation of Na + fluxes induced in brain slices by the neuroexcitant N-methyl-D-aspartic acid. γ-Kainylglutamic acid is also effective in protecting mice from picrotoxin-induced convulsions with an EC50 value of 0.17 μmol .
    γ-Kainylglutamic acid
  • HY-B0696S
    Tiagabine-d6

    NO050328-d6; NO328-d6; TGB-d6

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d6
  • HY-B0696AS
    Tiagabine-d4 hydrochloride

    NO050328-d4 hydrochloride; NO328-d4 hydrochloride; TGB-d4 hydrochloride

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d4 hydrochloride
  • HY-B0696AR
    Tiagabine hydrochloride (Standard)

    NO050328 hydrochloride (Standard); NO328 hydrochloride (Standard); TGB hydrochloride (Standard)

    		 Reference Standards GABA Receptor Neurological Disease
    Tiagabine (hydrochloride) (Standard) is the analytical standard of Tiagabine (hydrochloride). This product is intended for research and analytical applications. Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride (Standard)
  • HY-105296R
    Blarcamesine (Standard)

    		Reference Standards Sigma Receptor mAChR Cancer
    Blarcamesine (Standard) is the analytical standard of Blarcamesine (HY-105296). This product is intended for research and analytical applications. Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome .
    Blarcamesine (Standard)
  • HY-16579R
    Etifoxine hydrochloride (Standard)

    HOE 36-801 hydrochloride (Standard)

    		 GABA Receptor Reference Standards Neurological Disease
    Etifoxine (hydrochloride) (Standard) is the analytical standard of Etifoxine (hydrochloride). This product is intended for research and analytical applications. Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents .
    Etifoxine hydrochloride (Standard)
  • HY-105857
    Thiazesim

    		GABA Receptor Neurological Disease
    Thiazesim is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim exhibits specific pharmacological properties in animal experiments. Thiazesim reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim can be widely used in basic and clinical studies related to epilepsy .
    Thiazesim
  • HY-105857A
    Thiazesim hydrochloride

    		GABA Receptor Neurological Disease
    Thiazesim hydrochloride is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim hydrochloride exhibits specific pharmacological properties in animal experiments. Thiazesim hydrochloride reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim hydrochloride can be widely used in basic and clinical studies related to epilepsy .
    Thiazesim hydrochloride
  • HY-158252S
    Tiagabine-d5 hydrochloride

    NO050328-d5 hydrochloride; NO328-d5 hydrochloride; TGB-d5 hydrochloride

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d5 hydrochloride
  • HY-N16538
    4-(Acetoxymethyl)phenyl glucoside

    		Drug Derivative Cardiovascular Disease Neurological Disease
    4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .
    4-(Acetoxymethyl)phenyl glucoside
  • HY-B0696S1
    Tiagabine-d4

    NO050328-d4; NO328-d4; TGB-d4

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: